Formulation And In Vitro Characterization Of Haloperidol Nanosuspension For Intranasal Brain Delivery
DOI:
https://doi.org/10.64252/xg22dt91Keywords:
Haloperidol, Nanosuspension, Intranasal delivery, Brain targeting, Poloxamer 407, Blood–brain barrierAbstract
Background: Intranasal delivery offers a non-invasive route to bypass the blood–brain barrier, enhancing CNS drug targeting while minimizing systemic side effects. Haloperidol, a poorly water-soluble antipsychotic, was selected for nanosuspension formulation to improve solubility and brain delivery.
Objective: To formulate and evaluate haloperidol nanosuspensions for potential nose-to-brain delivery in CNS therapy.
Methods: Nanosuspensions were prepared via high-speed and high-pressure homogenization using Poloxamer 407 and Avicel as stabilizers. Evaluations included clarity, pH, viscosity, particle size, PDI, zeta potential, in vitro release, TEM imaging, and 90-day accelerated stability.
Results: The optimized formulation (NSH 6) with Poloxamer 407 showed clear appearance, pH 6.5, and viscosity of 16 cP. TEM revealed particles within 10–100 nm, though DLS indicated aggregation (>1000 nm). PDI was 0.1956; zeta potential –0.15 mV. In vitro release reached 89.93 ± 2.08% in 8h. Stability remained consistent over 90 days.
Conclusion: A stable haloperidol nanosuspension was successfully developed for intranasal delivery, showing enhanced drug release and brain-targeting potential. Further in vivo and toxicity studies are warranted.
